# GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

> **NCT01854294** · PHASE2 · COMPLETED · sponsor: **Genervon Biopharmaceuticals, LLC** · enrollment: 12 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** GM604
- **DRUG:** Placebo comparator

## Key facts

- **NCT ID:** NCT01854294
- **Lead sponsor:** Genervon Biopharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-04
- **Final completion:** 2014-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-04-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01854294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01854294, "GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01854294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*